Blocking a Liver Fat-Burning Gene Slashes LDL and ApoB Levels in Mice
Deleting CPT1a in mouse livers dramatically lowers ApoB-containing lipoproteins by accelerating clearance, revealing a new lipid metabolism target.
Summary
Researchers at the University of Kentucky discovered that deleting the gene CPT1a — which controls how the liver burns fatty acids via mitochondria — significantly lowers LDL cholesterol and ApoB-containing lipoprotein levels in mice. Paradoxically, the liver actually secretes more VLDL triglycerides and cholesterol when CPT1a is absent, meaning the lipid-lowering effect stems from faster clearance of these particles from the bloodstream, not reduced production. The mechanism involves stronger PPARα signaling, which boosts lipoprotein lipase activity and alters key regulatory proteins like ApoCII, ApoCIII, and Angptl3. These findings directly explain why human genetic variants and altered DNA methylation at the CPT1a gene are associated with lower VLDL cholesterol and triglycerides in population studies.
Detailed Summary
Cardiovascular disease risk is tightly linked to circulating levels of ApoB-containing lipoproteins — including LDL, VLDL, and IDL — yet the mechanisms connecting mitochondrial fatty acid oxidation to lipoprotein metabolism have remained poorly understood. Large-scale human genetic and epigenetic studies have repeatedly associated variants and altered methylation at the CPT1a locus with lower VLDL cholesterol and triglycerides, but whether this is causal and how it works mechanistically was unknown. This study set out to answer that question using a rigorous mouse genetic model.
The research team used an adeno-associated virus (AAV) expressing Cre-recombinase under a liver-specific TBG promoter to delete CPT1a selectively in hepatocytes of floxed Cpt1a mice. Two mouse lines were tested: standard Cpt1a-floxed mice and a line also carrying the human APOB100 transgene, which more closely mimics human lipoprotein biology. Both sexes were studied, and animals were placed on either a low-fat control diet or a Western-type diet (42% kcal fat, 0.2% cholesterol) for 16 weeks. Lipoprotein composition was analyzed by both size exclusion chromatography and nuclear magnetic resonance (NMR) spectroscopy, providing detailed particle number and size data.
The liver-specific knockout (LKO) mice showed consistently lower circulating ApoB levels, reduced LDL cholesterol, and lower LDL particle number compared to controls — findings replicated in both the standard and APOB100-transgenic backgrounds. Critically, when VLDL secretion rates were measured after lipase inhibition with poloxamer 407, LKO mice actually secreted more VLDL-triglyceride and VLDL-cholesterol than controls. This counterintuitive result rules out reduced hepatic lipid output as the explanation and instead points firmly to accelerated peripheral clearance of ApoB-containing lipoproteins as the dominant mechanism.
Mechanistic analysis revealed significantly enhanced PPARα transcriptional signaling in LKO livers. This drove upregulation of ApoAIV and ApoCII — both activators of lipoprotein lipase — and downregulation of ApoCIII and Angptl3, two well-established inhibitors of lipoprotein lipase activity. The net effect is a strongly pro-lipolytic environment in which VLDL particles are processed and cleared more rapidly. Bulk RNA sequencing confirmed broad PPARα target gene activation, consistent with a shift in hepatic energy sensing when mitochondrial beta-oxidation is blocked. Lipid droplet accumulation in the liver was also observed in LKO mice, reflecting the rerouting of fatty acids away from mitochondrial oxidation.
These findings carry significant translational implications. The human GWAS and epigenome-wide association data linking CPT1a variants and methylation to lower VLDL cholesterol now have a clear mechanistic explanation: reduced CPT1a activity triggers PPARα-driven remodeling of the lipoprotein clearance machinery. This positions CPT1a as a potential pharmacological target for lowering atherogenic lipoproteins, though the hepatic lipid accumulation observed in LKO mice raises important safety considerations — blocking mitochondrial fat oxidation in the liver could promote steatosis and potentially MASLD, requiring careful therapeutic window assessment before any clinical translation.
Key Findings
- Liver-specific deletion of CPT1a reduced circulating ApoB levels and LDL particle number in both standard and human APOB100-transgenic mice on control and Western-type diets
- Despite lower plasma lipids, VLDL-triglyceride and VLDL-cholesterol secretion rates were increased in LKO mice after poloxamer 407 lipase inhibition, indicating accelerated lipoprotein clearance rather than reduced secretion
- CPT1a LKO mice showed significantly elevated PPARα target gene expression, including upregulation of ApoCII and ApoAIV — activators of lipoprotein lipase
- Angptl3 and ApoCIII, two potent inhibitors of lipoprotein lipase, were downregulated in LKO livers, collectively creating a strongly pro-lipolytic plasma environment
- Human GWAS data confirmed significant associations between CPT1a SNPs and reductions in plasma cholesterol, validating the mouse model's translational relevance
- Positive correlations between hepatic Cpt1a expression and plasma cholesterol levels were confirmed across multiple inbred mouse strains, supporting a conserved regulatory relationship
- LKO mice developed hepatic lipid accumulation, indicating that blocking mitochondrial fatty acid oxidation reroutes fatty acids into storage and raises MASLD risk
Methodology
Eight-week-old male and female Cpt1a-floxed mice, with and without the human APOB100 transgene, received liver-specific AAV-TBG-Cre or control AAV and were fed low-fat or Western-type diet (42% kcal fat, 0.2% cholesterol) for 16 weeks. Lipoprotein profiling used size exclusion chromatography and NMR spectroscopy; VLDL secretion rates were measured via poloxamer 407 lipase inhibition. Hepatic gene expression was assessed by bulk RNA sequencing and immunoblotting, and bile acids and fecal neutral sterols were quantified by LC/GC-mass spectrometry.
Study Limitations
This study was conducted entirely in mice, and while the human APOB100-transgenic model improves translational relevance, direct human validation of the CPT1a-PPARα-lipoprotein axis is still needed. The liver-specific knockout model completely abolishes CPT1a activity, which may not reflect the partial reduction associated with human SNPs or methylation changes. The authors note that hepatic lipid accumulation in LKO mice raises safety concerns for any therapeutic targeting of this pathway, and potential sex-specific differences were not fully explored in the published findings.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.